Basilea Pharmaceutica AG (SWX:BSLN)

Basilea Pharmaceutica AG Income Statement

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	212.1	194.87	150.28	122.32	131.56	112.42
Other Revenue	24.12	13.68	7.36	25.45	16.56	15.21
Revenue	236.21	208.54	157.63	147.77	148.12	127.63
Revenue Growth (YoY)	58.51%	32.30%	6.68%	-0.24%	16.06%	-5.03%
Cost of Revenue	126.63	115.82	104.65	98.41	117.23	121.46
Gross Profit	109.58	92.72	52.99	49.36	30.89	6.17
Selling, General & Admin	33.01	31.02	31.08	28.55	27.89	27.58
Operating Expenses	33.01	31.02	31.08	28.55	27.89	27.58
Operating Income	76.57	61.7	21.91	20.81	3.01	-21.41
Interest Expense	-3.75	-4.34	-11.2	-9.85	-8.15	-7.59
Interest & Investment Income	1.34	1.42	1.69	0.33	0.07	0.1
Other Non Operating Income (Expenses)	-1.88	1.49	-1.94	0.81	-1.24	-0.49
EBT Excluding Unusual Items	72.28	60.26	10.46	12.1	-6.31	-29.39
Gain (Loss) on Sale of Assets	-	-	-	-	0.02	15.04
Other Unusual Items	-	-	-	-	-0.5	-0.31
Pretax Income	72.28	60.26	10.46	12.1	-6.79	-14.67
Income Tax Expense	-0.38	-17.33	0.01	-0.05	0.04	0.06
Net Income	72.66	77.59	10.45	12.15	-6.83	-14.72
Net Income to Common	72.66	77.59	10.45	12.15	-6.83	-14.72
Net Income Growth	-	642.45%	-13.96%	-	-	-
Shares Outstanding (Basic)	12	12	12	12	12	10
Shares Outstanding (Diluted)	14	14	12	12	12	10
Shares Change (YoY)	15.14%	14.10%	1.67%	2.24%	13.62%	-4.41%
EPS (Basic)	5.97	6.42	0.87	1.02	-0.58	-1.43
EPS (Diluted)	5.47	5.82	0.86	1.02	-0.58	-1.43
EPS Growth	-	577.28%	-15.69%	-	-	-
Free Cash Flow	77.94	72.65	13.43	3.92	-32.6	-55.96
Free Cash Flow Per Share	5.62	5.24	1.11	0.33	-2.79	-5.44
Gross Margin	46.39%	44.46%	33.62%	33.40%	20.86%	4.83%
Operating Margin	32.41%	29.59%	13.90%	14.09%	2.03%	-16.78%
Profit Margin	30.76%	37.21%	6.63%	8.22%	-4.61%	-11.54%
Free Cash Flow Margin	32.99%	34.84%	8.52%	2.65%	-22.01%	-43.84%
EBITDA	78.07	63.13	23.19	21.71	3.56	-20.32
EBITDA Margin	33.05%	30.27%	14.71%	14.69%	2.40%	-15.92%
D&A For EBITDA	1.51	1.43	1.28	0.9	0.55	1.09
EBIT	76.57	61.7	21.91	20.81	3.01	-21.41
EBIT Margin	32.41%	29.59%	13.90%	14.09%	2.03%	-16.78%
Effective Tax Rate	-	-	0.10%	-	-	-
Revenue as Reported	236.21	208.54	157.63	147.77	148.12	127.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.